STADA

STADA is a global pharmaceutical company that operates in the consumer healthcare, generics, and specialty pharma markets. The company serves a diverse range of clients including healthcare professionals, pharmacies, and consumers. STADA's business model is built on a three-pillar strategy: consumer healthcare products, generics, and specialty pharmaceuticals. This diversified approach allows the company to generate revenue through the sale of over-the-counter (OTC) products, prescription medications, and specialized treatments. In the financial year 2023, STADA achieved group sales of EUR 3,734.8 million and reported earnings before interest, taxes, depreciation, and amortization (EBITDA) of EUR 802 million. With a workforce of 11,466 employees worldwide, STADA continues to focus on its mission of bringing health to society. The company has a long history dating back to 1895 and has consistently expanded its portfolio through strategic acquisitions and partnerships. Recent activities include a 60% investment in the Italian New Pharmajani SpA and the acquisition of brand products from redinomedica AG for the German OTC market. STADA is committed to transparency and compliance, adhering to the Medicines for Europe Code of Conduct and other regulatory standards.

Keywords: consumer healthcare, generics, specialty pharma, OTC products, prescription medications, strategic acquisitions, global presence, healthcare professionals, pharmacies, compliance.